Brazil now has its own semaglutide injection made on national soil. Learn how Ozivy works, what makes it different from existing options, and what it could mean for access to GLP-1 therapies in the country.
Until recently, every semaglutide available in Brazil arrived from abroad or was assembled locally with imported active ingredient. The entry of a product manufactured entirely in Brazil marks a meaningful shift in a market where supply chain hiccups and currency swings have historically shaped availability. Ozivy is the name drawing attention among healthcare professionals and patients alike, and understanding what it brings to the table matters for anyone following the GLP-1 landscape in the country.
What Is Ozivy and Where Does It Come From
Ozivy is a subcutaneously injected semaglutide product developed and manufactured by a Brazilian pharmaceutical company for the domestic market. Unlike generic versions of existing medications that replicate the reference product, Ozivy received its own registration with ANVISA, Brazil's health regulatory agency, as a product developed under the country's own regulatory pathway for new pharmaceutical products.
To understand what sets Ozivy apart, it helps to look at the existing Brazilian market. The reference product for semaglutide in injectable form comes from Novo Nordisk. Eurofarma brought a generic version called Poviztra to market, relying on imported bulk drug substance. Ozivy, by contrast, carries the distinction of having its entire manufacturing process — from synthesis of the active pharmaceutical ingredient to fill-finish into the final delivery system — carried out on Brazilian industrial soil.
The product received registration with ANVISA and became available in caneta preenchida — a pre-filled pen — format, which patients self-administer via subcutaneous injection on a weekly schedule. This presentation matches what is commonly used for injectable GLP-1 therapies and aligns with the dosing conventions established by the reference product.
The Science Behind Semaglutide and How Ozivy Acts in the Body
Semaglutide belongs to the class of medications known as GLP-1 receptor agonists. The name comes from glucagon-like peptide-1, a hormone the intestine naturally releases after eating. When food enters the stomach, GLP-1 signals the brain to reduce appetite and tells the digestive system to slow down.
Ozivy's active ingredient, semaglutida, works by binding to GLP-1 receptors in the hypothalamus — the brain region that controls hunger and satiety. Once the receptor is activated, it triggers a cascade that reduces food-seeking behavior and lowers overall caloric intake. At the same time, semaglutide slows gastric emptying, meaning food stays in the stomach longer and patients feel full sooner and for a greater duration after meals.
One practical advantage of semaglutide over older diabetes and weight management drugs is its long half-life. The molecule was engineered to resist rapid breakdown, allowing it to remain active in the bloodstream for approximately one week. This property makes weekly injections possible and consistent, rather than requiring daily dosing. The oral version of semaglutide, sold under a different brand name, works through a different absorption mechanism in the gut and demands daily administration, which some patients find less convenient than a single weekly injection.
Ozivy's formulation delivers this same established mechanism of action, allowing the drug to act on both central appetite pathways and peripheral digestive processes simultaneously.
Why Domestic Manufacturing Makes a Difference
The Brazilian pharmaceutical market has long depended on imported finished products or imported active ingredients for locally assembled medications. This dependency creates exposure to two recurring problems: exchange rate volatility and international logistics disruptions.
When the local currency weakens against the dollar or euro, imported medications become more expensive to produce and sell in Brazil, often leading to price increases that reach patients. International shipping delays, port congestion, and customs bottlenecks have, at various points, caused temporary shortages of medications that patients rely on continuously. For a therapy like semaglutide, where missing a dose or stopping treatment can affect metabolic control, supply consistency is not merely a logistical concern — it is a clinical one.
Having Ozivy produced domestically means the supply chain for the active ingredient and the finished product operates primarily in reais and within Brazilian regulatory oversight. ANVISA inspects domestic manufacturing facilities under its Good Manufacturing Practice requirements, which apply the same quality standards used globally. For patients and physicians, this may translate into more predictable availability and pricing over time, though the extent of that impact will depend on how the manufacturer scales production and manages distribution.
Domestically produced medications also carry greater potential for inclusion in public health programs. Medications manufactured within Brazil have historically faced fewer barriers to procurement by the Ministry of Health, which supplies the Unified Health System (SUS). While it is too early to say whether Ozivy will be incorporated into public distribution programs, the groundwork of domestic production makes that pathway more accessible than it would be for a fully imported product.
Where Ozivy Stands in the Brazilian GLP-1 Market
The injectable semaglutide market in Brazil now includes the original reference product, Eurofarma's generic Poviztra, and Ozivy. Each occupies a different position in terms of pricing, regulatory status, and manufacturing origin. The reference product typically commands the highest retail price, while generics and domestically produced options generally enter the market at lower price points once approved and released by CMED, the agency that regulates medication pricing in Brazil.
Ozivy's target population overlaps with that of other GLP-1 agonists in the country. The approved indication covers patients with type 2 diabetes who need glycemic control, and treatment of obesity or overweight in patients with at least one weight-related comorbidity, per the label approved by ANVISA. This dual indication mirrors the established profile of the reference product and places Ozivy squarely in the same clinical territory as existing options.
From a practical standpoint, patients choosing between Ozivy and alternatives like Poviztra may notice differences in the delivery device, pen design, available dose strengths, and cost. Physicians may consider these factors alongside clinical efficacy when making prescribing decisions for individual patients.
What Ozivy's Arrival Changes for Access to GLP-1 Therapies
The presence of a third significant player in the injectable semaglutide space introduces real competitive dynamics. With two generics now available alongside the reference product, pharmacies and distributors have more negotiating room. This competition may help stabilize or gradually reduce retail prices, making treatment more affordable for patients who currently pay out of pocket.
For patients who have been waiting for medication through exceptional import channels — a process that can take months and involves customs procedures — a domestic alternative that is already registered with ANVISA and distributed through Brazilian pharmacy networks offers a potentially faster and more straightforward path to treatment. Patients no longer need to navigate import licenses or wait for international shipments if their physician determines Ozivy is an appropriate choice.
The expansion of the GLP-1 market in Brazil also creates more talking points when patients and physicians engage with health insurers about coverage. Plans that previously declined to include GLP-1 therapies in their formularies may face renewed pressure as lower-cost options enter the market and the overall treatment base grows.
OzemNews continues to follow the developments in this space, tracking how pricing, distribution, and clinical adoption evolve as Brazilian-made semaglutide products become more established in the market.
FAQ
What type of medication is Ozivy?
Ozivy is an injectable GLP-1 receptor agonist containing semaglutide as its active ingredient. It is administered once weekly via subcutaneous injection using a pre-filled pen.
How is Ozivy different from the generic semaglutide already sold by Eurofarma?
Eurofarma's generic version relies on imported active pharmaceutical ingredient, while Ozivy is manufactured entirely within Brazil, from synthesis of the active ingredient through the final drug product.
Can Ozivy be used for weight loss?
Ozivy's approved label in Brazil includes indications for both type 2 diabetes management and treatment of obesity or overweight in patients with weight-related comorbidities. A healthcare provider determines eligibility based on the patient's clinical profile.
Does Ozivy require refrigeration?
Semaglutide products typically require refrigeration before first use and may be stored at room temperature for a limited period after first puncture, following the storage instructions in the approved package insert.
Will Ozivy be covered by health insurance plans in Brazil?
Coverage varies by plan and operator. The entry of lower-cost alternatives into the market may increase pressure on insurers to include GLP-1 therapies in their formularies, but individual coverage decisions depend on each plan's policies.
Sources
Disclaimer: This content is for informational purposes only and does not replace professional medical advice. Always consult your doctor before starting, changing or stopping any treatment.
Ozempro — Monitor GLP-1
Never miss a dose and track everything
Injection reminders, a dose history and a side-effects diary — all organized to bring to your appointment.
or download the app
